Overview

A Study of ARC1905 (Anti-C5 Aptamer) in Subjects With Dry Age-related Macular Degeneration

Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
The objectives of this study are to evaluate the safety and tolerability of ARC1905 intravitreous injection in subjects with geographic atrophy secondary to dry age-related macular degeneration (AMD).
Phase:
Phase 1
Details
Lead Sponsor:
Ophthotech Corporation